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Abstract
It is widely thought that pregnancy reduces breast cancer risk, but this lacks consideration of breast cancer subtypes. While
a full term pregnancy reduces risk for estrogen receptor positive (ER+) and luminal breast cancers, parity is associated with
increased risk of basal-like breast cancer (BBC) subtype. Basal-like subtypes represent less than 10% of breast cancers and
are highly aggressive, affecting primarily young, African American women. Our previous work demonstrated that high fat
diet-induced obesity in nulliparous mice significantly blunted latency in C3(1)-TAg mice, a model of BBC, potentially through
the hepatocyte growth factor (HGF)/c-Met oncogenic pathway. Experimental studies have examined parity and obesity
individually, but to date, the joint effects of parity and obesity have not been studied. We investigated the role of obesity in
parous mice on BBC. Parity alone dramatically blunted tumor latency compared to nulliparous controls with no effects on
tumor number or growth, while obesity had only a minor role in further reducing latency. Obesity-associated metabolic
mediators and hormones such as insulin, estrogen, and progesterone were not significantly regulated by obesity. Plasma IL-
6 was also significantly elevated by obesity in parous mice. We have previously reported a potential role for stromal-derived
hepatocyte growth factor (HGF) via its cognate receptor c-Met in the etiology of obesity-induced BBC tumor onset and in
both human and murine primary coculture models of BBC-aggressiveness. Obesity-associated c-Met concentrations were
2.5-fold greater in normal mammary glands of parous mice. Taken together, our studies demonstrate that, parity in C3(1)-
TAg mice dramatically reduced BBC latency compared to nulliparous mice. In parous mice, c-Met is regulated by obesity in
unaffected mammary gland and is associated with tumor onset. C3(1)-TAg mice recapitulate epidemiologic findings such
that parity drives increased BBC risk and potential microenvironmental alterations in c-Met signaling may play a role in
etiology.
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Introduction
Epidemiologic and experimental data have shown that a full
term pregnancy reduces breast cancer risk [1]. However, with the
advent of protein and mRNA expression profiling and the Tumor
Cancer Genome Atlas (TCGA), classification of tumor subtypes
with specific risks and outcomes has shed new light on breast
cancer incidence [2,3]. BBC represents 5–10% of breast cancers
[4]. BBCs are estrogen receptor-, progesterone receptor- and
human epidermal growth factor receptor 2 (HER2)- negative,
thus, often referred to as triple-negative breast cancers, and as such
these cancers lack a targeted therapy [5]. Patients have poor
overall survival because these tumors are highly proliferative.
Tumors are diagnosed predominantly in young African-American
women, particularly obese women [6–8]. While a full term
pregnancy reduces risk for estrogen receptor-positive breast
cancers, like the luminal subtype [1], parity is actually associated
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with increased probability of developing the more aggressive basal-
like breast cancer (BBC) subtype [7,9–12].
The choice of mouse model is critical in modeling breast cancer
subtypes. Protective effects of pregnancy have been described in
luminal subtype models wherein parity antagonized the effects of
carcinogens such as dimethylbenzanthracene (DMBA) [13,14] and
ionizing radiation [15]. The protective effect of pregnancy can be
mimicked by exogenous administration of high levels of estrogen
and progesterone [16]. However, to date there have been no such
studies on the effects of parity on BBC onset in murine models. We
have shown that BBC is characterized by unique epithelial-stroma
interactions, which likely play a role in etiology [17–22]. Gatenby
and Gillies speculate that the origin of cancer may lie not in
mutations within epithelial cells, but within acquired or somatic
mutations in the mesenchymal cells that control tissue structure
[23]. Thus, we hypothesized that pregnancy would induce long
term changes such as inflammatory and metabolic alterations in
the breast microenvironment that promote BBC [19,24].
Parity is often associated with excess weight gain and retention
of weight after delivery, which is especially true for African
American women, who gain more weight than recommended by
the Institute of Medicine and retain more of that weight
postpartum [25]. Obesity is a well-known risk factor for many
cancers [26], with heterogeneous effects on breast cancer risk
when subtypes and/or menopausal status are taken into account.
For breast cancer overall, results for which are dominated by the
most prevalent luminal subtype, postmenopausal obesity is a risk
factor, while premenopausal obesity appears to have modest
protective effects [27–29]. However for BBC, body mass index
and/or waist hip ratio are significantly associated with risk,
regardless of age or menopause status [10,30–33]. Using nullipa-
rous C3(1)-TAg mice, a unique genetically engineered murine
model (GEMM) of BBC [4,34], we reported that obesity reduced
latency and induced tumor cell aggressiveness, which is the first
work in preclinical models paralleling human epidemiologic BBC
findings [35]. Furthermore, we reported that weight loss prior to
tumor onset reduced tumor progression [21]. Hence, the role of
obesity in BBC is established through epidemiologic and
experimental findings; however, the underlying mechanisms of
obesity-induced risk remain uncertain.
Since obesity is known to drive BBC onset and obesity is often
linked to parity, interactions with parity were investigated to gain
further mechanistic insight. Using C3(1)-TAg mice, we examined
the effects of parity and obesity on tumor latency and progression.
Parity alone dramatically blunted tumor latency when compared
to previous findings in nulliparous mice [35]. In parous mice,
obesity had only a minor role in reducing mean latency compared
to lean parous mice. We have previously shown that stromal-
derived hepatocyte growth factor (HGF/scatter factor) and its
cognate receptor c-Met correlated with obesity-induced BBC
tumor onset in nulliparous mice [22] and were reduced with
weight loss [21]. HGF also mediated in vitro measures of BBC-
aggressiveness in murine and human primary coculture models
[36,37]. Herein, we demonstrate that in parous mice, c-Met is
elevated by obesity in the normal mammary gland which
correlated with tumor onset. Systemic measures of cytokines and
hormones were not significantly different except for obesity-
induced increases in Il-6. Thus, parity in C3(1)-TAg mice reduced
latency to the same extent as obesity in nulliparous mice.
Materials and Methods
Reagents
c-Met goat anti-mouse antibody (detects pro- and cleaved c-
Met) was obtained from R&D Systems (Minneapolis, MN). Anti-
SV40-TAg was obtained from Santa Cruz (Santa Cruz, CA).
Estrogen and progesterone ELISA kits were obtained from
Novatein Bio (Cambridge, MA).
C3(1)-TAg Mouse Model
Diets: C3(1)-TAg mice [34] were used to study the role of obesity
and parity on BBC. Studies were performed with approval and in
accordance with guidelines of the Institutional Animal Care and
Use Committee at the University of North Carolina at Chapel Hill
(UNC-CH, NC). Female C3(1)-TAg mice were obtained through a
collaboration with the UNC Lineberger Comprehensive Cancer
Center (LCCC) Mouse Phase I Unit (MP1U). Female mice at
seven weeks of age were placed with male mice for breeding.
Males were removed at pregnancy. Following the delivery of
litters, at maternal age of approximately 10 weeks old, pups were
removed immediately after birth, and the mothers were randomly
assigned to diet groups. Ten percent kcal from fat diet (‘‘10%’’) or
60% kcal (‘‘60%’’) lard-based diets matched for protein, vitamins,
and minerals were obtained from Research Diets Inc. (New
Brunswick, NJ) after customization, as in [36]. Custom diet
information can be found in Table S1.
Tumor latency, number, growth and volume. Mice were
monitored for tumor development by palpating thrice weekly
following initiation of diets at 10 weeks of age. Initial tumor
latency was defined as age at detection of first tumor and is
reported as mean 6 standard deviation (Table 1). Total tumor
latency was defined as latency of all tumors palpated until sacrifice
and is reported as Kaplan-Meier plot. Tumor volumes were
measured once weekly over 3 weeks, following detection of first
tumor, using ultrasound measurements with the Visualsonics 2000
(Toronto, Canada)) as in [36]. The tumor volumes were calculated
using the formula: length6width260.5. The percent change in
volume over time was calculated: (End volume – start volume)/
Start volume * 100. The number of tumors per mouse was
counted at sacrifice.
Body weight and composition. Prior to starting mice on
diet and weekly until sacrifice, body weight was measured in
grams. Body composition including lean mass, fat mass, free water
content and total water content of non-anesthetized mice was
measured prior to initiating diet and monthly thereafter using the
EchoMRI-100 quantitative magnetic resonance whole body
composition analyzer (Echo Medical Systems, Houston, TX).
Obesity is defined as greater than a 5% incremental increase in fat
composition. Fat mass is presented as % fat mass over total body
weight measured day of MRI.
Blood glucose. Blood glucose was measured prior to start of
diet and at sacrifice following a 6 h fast using a Bayer Contour
Blood Glucose Monitor (Bayer HealthCare LLC, Tarrytown, NY).
Tissue harvest. 3 weeks after detection of the first tumor,
mice were sacrificed by an intraperitoneal (i.p.) injection of avertin
(Fisher Scientific, Pittsburgh, PA). Following euthanasia, blood was
collected by cardiac puncture in a tube with 10 ml of 0.05 mM
EDTA. Plasma was collected by centrifuging blood at 50006g for
5 min. Mammary glands without palpable or visible tumors were
collected as normal unaffected gland, although atypia of ductal
epithelium could be present in C3(1)-TAg mice after 8 weeks of age
[34]. Portions of the tissues were placed into a cassette and
formalin fixed for immunohistochemical (IHC) analysis.
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Plasma hormone panel. Plasma collected at sacrifice was
used for measuring metabolically relevant hormones and inflam-
matory mediators (insulin, IL-6, MCP-1 and TNF-a) using the
Milliplex MAP Mouse Metabolic Hormone Magnetic Bead Panel
in the Luminex MAGPIX system (EMD Millipore, Billerica, MA).
The homeostasis model assessment-insulin resistance (HOMAIR)
was used to calculate the approximate insulin resistance using the
formula (glucose (mg/dl at sacrifice)6insulin (at sacrifice)/405) as
previously described [21,36]. Estrogen and progesterone plasma
concentrations were measured using ELISA assays following the
manufacturer’s protocol (Novatein Bio; Cambridge, MA).
IHC of c-Met and SV40 TAg in Normal Mammary Glands
and Tumors
IHC for c-Met and SV40 T antigen (TAg) was performed in
normal mammary glands and tumors using methods as described
[36,38]. Stained slides were scanned into the Aperio Scanscope CS
system (Aperio Technologies, Vista, CA) at a magnification of
40X. Sections were then analyzed quantitatively using the Aperio
Imagescope software: membrane IHC algorithm for c-Met
quantification and the positive pixel counts for diaminobenzidine
(DAB) staining in the color deconvolution algorithm for TAg as in
[36]. N= 6 random areas from sections (n = 2 per mouse) were
quantified and averaged per tumor per animal (n = 5 mice per diet
exposure group). Images (40X) shown are representative.
Statistical Analysis
Raw data are available in Table S2. Data in all cases are
expressed as mean 6 standard error of the mean (S.E.M.).
Comparison of mean was carried out using a one-way analysis of
variance (ANOVA) analysis with the SPSS (version 20) software
(IBM SPSS Statistic 20.0, Armonk, NY). The level of significance
was set at P,0.05. Kaplan-Meier analyses were conducted using
GraphPad Prism 5 software to estimate tumor latency. Log rank
and chi-square tests were used to investigate differences among
groups. P values,0.05 were considered statistically significant.
Results
Parity and obesity reduce C3(1)-TAg basal-like tumor
latency
To determine if parity or parity and obesity altered tumor onset
in C3(1)-TAg BBC mice, age-matched parous mice were fed
control (10% kcal from fat) or obesogenic (60% kcal from fat) diets.
Parity significantly decreased latency in lean mice fed 10% diet
compared to previous reports in nulliparous mice fed identical
diets (Table 1 [36]). In lean control mice fed 10% diet, parity
decreased latency by almost 2.5 weeks (Table 1, P = 0.001).
However, in obese mice fed 60% diet, the effect of parity on
latency was not significantly different compared to obese
nulliparous mice.
Within parous mice, no significant effects were detected on
median initial tumor latency (data not shown) or total tumor
latency (initial (first tumor) plus subsequent tumors detected until
sacrifice) (Figure 1A). The hazard ratio comparing median
latencies of 18.00 weeks for 10%-fed mice to 17.43 for 60%-fed
mice was 1.151 (95% CI of ratio: 0.67 to 1.98). However, obesity
significantly reduced mean latency (Figure 1B, P= 0.002). There
were no significant alterations in tumor number at sacrifice or
tumor volume changes over three weeks from time of tumor
identification until sacrifice in parous mice (data not shown).
c-Met expression in normal mammary glands and tumors
correlated with tumor latency
Significant effects of parity on latency but not tumor burden or
progression in the C3(1)-TAg GEMM suggested that effects of
parity were occurring early in tumorigenesis to significantly alter
tumor onset. Previous work by our group has demonstrated a role
for obesity-mediated HGF/c-Met signaling in normal mammary
gland of nulliparous C3(1)-TAg mice [36] which was reversed by
weight loss [21]. In the current study, normal mammary glands
from parous mice were examined for c-Met receptor expression. c-
Met expression in normal mammary gland from 60%-fed mice
demonstrated primarily epithelial localization (Figure 1C). Digital
quantification revealed that c-Met protein concentrations were
significantly increased by 2.5-fold in obese 60% (P= 0.003)-fed
mice compared with 10%-fed controls (Figure 1D). Interestingly in
tumors, c-Met protein levels were significantly decreased in obese
60% (P= 0.042)-fed mice compared with 10%-fed controls (data
not shown).
Metabolic mediators, but not pregnancy hormones or
TAg expression, in normal mammary glands and tumors
associated with decreased latency
To determine if metabolic parameters correlated with tumor
onset, body weight and composition were measured. Parous mice
fed 60% diets were significantly heavier compared with 10%-fed
mice (P,0.05, Figure 2A). Compared to mice on 10% diet, 60%-
fed mice also exhibited greater fat mass at 4 weeks on diet
(P = 0.0001), and at 8 weeks (60% P=0.0049, Figure 2B) as
measured by MRI. Glucose, insulin and HOMAIR measures did
not vary by diet exposure in parous C3(1)-TAg mice (Figures 2C–
E).
Systemic inflammatory mediators were also examined as
potential contributors to tumor onset [35]. IL-6 was significantly
elevated in obese mice (P= 0.03) compared to 10%-fed controls
(Figure 3A). However, other chemokine and cytokines markers of
systemic inflammation including MCP-1 and TNF-a were not
modified by diet (Figure 3B and C). Estrogen and progesterone
concentrations were similar between lean and obese mice
(Figure 3D and E).
To establish that parity or diet exposure did not alter expression
of the oncogenic transgene SV40 T-antigen driven by the C3
Table 1. Tumor latency in C3(1)-TAg nulliparous and parous mice.
Table 1 Nulliparous [35] Parous p-value
10% 18.9960.59 16.5060.38 0.001
60% 16.9460.51 15.9160.47 .0.05
Initial tumor latency was defined as the age at which first tumor palpated. Mean 6 standard error of mean of tumor latency of the first tumor palpated. N = 15 per
group.
doi:10.1371/journal.pone.0111394.t001
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Figure 1. Obesity and parity regulated a decrease in BBC latency and elevated c-Met in normal mammary glands. A) Upon initiation of
diet at 10 weeks of age, parous mice were palpated three times a week for tumor onset (first tumor detected) (N= 15). Using the Kaplan-Meier
analysis the hazard ratio comparing 60% to 10% was 1.151 (95% CI of ratio: 0.67 to 1.98). Median latencies in 10% and 60%-fed mice were 18.00 and
17.43 weeks, respectively. Using a chi-square test with a degree of freedom of 1, 10% vs. 60% equaled 0.61. B) Mean latencies of total tumors
palpated from initial until sacrifice are shown. N = 30 tumors in 15 mice per group. *P = 0.002. C) Representative 40X photomicrographs of the IHC
analysis of membrane localized c-Met staining (arrows). D) Total c-Met protein levels in normal mammary glands were quantified. *P = 0.003.
doi:10.1371/journal.pone.0111394.g001
Figure 2. Diet-induced obesity affects body weight, adiposity, and leptin but not metabolic parameters in parous mice. A) C3(1)-TAg
body weight was measured weekly over the course of the study until mice were sacrificed. Diet was initiated at 10 weeks of age (week 0 on diet) in
n = 15 mice. *P,0.05 over weeks 1–6. B) Body fat content by MRI was measured monthly until sacrifice. Percent fat content over total body mass is
shown. n = 15. *P,0.0001 at 4 weeks on diet, and P= 0.0049 at 8 weeks on diets. C) Blood glucose levels were measured from tail vein blood in mice
fasted 6 hours. n = 15 mice. D) Insulin was measured at sacrifice in 6 hour fasted mice. n = 12. E) Homeostasis model assessment of insulin resistance
(HOMAIR) was calculated from measures at sacrifice. n = 12.
doi:10.1371/journal.pone.0111394.g002
Parity Blunts BBC Latency
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promoter, which is the key driver of tumorigenesis in this model,
IHC was undertaken and digitally quantified. No significant
differences were observed in the SV40-TAg expression in the
normal mammary glands (Figures 4A and B). In the tumors, there
was in fact a significant decrease in the SV40 TAg expression levels
in the 60% group compared with the 10% diet-fed mice
(P = 0.044) (data not shown).
Discussion
While pregnancy generally protects against the development of
hormone-responsive estrogen and progesterone receptor positive
tumors [39], it is an established risk factor for BBC. The Carolina
Breast Cancer Study, among others, has identified parity as a
positively associated risk factor for the development of BBC in
both pre- and postmenopausal women [8,9,26,34,40,41]. Similar-
ly, while pre-menopausal obesity is associated with protection from
the development of luminal breast cancers (the most prevalent
subtype), both pre- and post-menopausal obesity are associated
with increased BBC risk [7]. The convergence of pregnancy and
obesity is an important public health concern in relation to BBC
risk. During the reproductive years (approximately age 20–39),
roughly 25% of non-Hispanic whites are obese (BMI$30), and
prevalence of obesity is approximately twice that in non-Hispanic
black Americans (53.9% obese in 2003–2004) [42]. Since, obesity
is a national epidemic in the United States [6] and BBC is a triple
negative subtype that has no targeted therapies [5], it is important
to understand the interaction between obesity and parity in
relation to BBC risk.
Pregnancies cause extensive tissue remodeling, with the
epithelium filling the majority of the mammary fat pad. Stromal
cells including adipocytes, fibroblasts, and immune cells are
important components of the mammary gland that work in
concert to regulate the gland as it changes to produce milk during
lactation. After weaning, tissue remodeling called involution causes
the mammary gland to return to a microenvironmental architec-
ture similar to the virgin gland [43,44]. These developmental
changes and alterations in microenvironment may represent
opportunities for carcinogenesis and may further interact with
Figure 3. IL-6 concentration was elevated but plasma levels of other inflammatory mediators and reproductive hormones were not
increased by obesity in parous mice. Cytokine and chemokine concentrations of A) IL-6, B) TNF-a and C) MCP-1 were measured in plasma at
sacrifice. n = 12. *P = 0.028. D) Plasma estrogen levels were determined using ELISA analysis. n = 14. E) Plasma progesterone levels were determined
using ELISA analysis. n = 14.
doi:10.1371/journal.pone.0111394.g003
Figure 4. Normal mammary gland and tumor levels of SV40-TAg are not increased by obesity in parous mice. A) Representative 20X
photomicrographs of SV40 T-antigen (TAg) staining in normal mammary gland (A). Arrows indicate positive SV40 TAg staining. B) SV40 TAg levels in
normal mammary glands (B) were quantified. n = 2 sections from 5 mice per diet group were digitally quantified. *P = 0.044.
doi:10.1371/journal.pone.0111394.g004
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other environmental exposures, such as dietary fat exposure and
the obese state.
Using C3(1)-TAg mice, a BBC GEMM that represents human
BBC [4], our previous work examining nulliparous mice
demonstrated that obesity lead to a significant two week reduction
in latency compared to lean controls [36]. Herein, we demon-
strated that in lean mice parity alone significantly shortened BBC
latency compared to nulliparous controls. However, in obese mice,
the effect of parity was lost because parity did not reduce latency
further than obesity alone. Within parous mice, obesity did not
reduce median latency of the first tumor detected. However
obesity significantly reduced secondary and subsequent mean
tumor latency compared to lean controls. There were no effects on
total tumor burden or promotion which was similar to findings in
nulliparous mice [36]. Taken together, parity-induced reductions
in latency may leave little opportunity for dramatic effects of
obesity-associated factors that were observed in nulliparous mice.
The C3(1)-Tag parous mouse model experiences tumorigenesis at
a young age (akin to BBC in humans) [8], and thus poses a
challenge for studying the joint effects of parity and obesity.
Obesity leads to numerous changes in the stroma of the
mammary microenvironment and other fat pads including the
release of growth factors and regulation of growth factor receptors
[36,38,45–48]. The HGF/c-Met axis is a pathway that is linked to
both obesity and breast cancer risk [21]. c-Met activation drives
cell proliferation, angiogenesis, differentiation, migration, and
anti-apoptosis pathways [49–51]. In nulliparous C3(1)-TAg mice,
c-Met protein levels were significantly elevated by obesity in
normal mammary gland and tumors [36]. Herein, we demon-
strated that obesity also significantly elevated c-Met protein levels
in the normal mammary glands in parous mice. However, cMet
was not elevated by obesity in tumors with parity, although this
was just a single measure on tumors isolated at sacrifice. It may be
possible that obesity creates a dysfunctional microenvironment in
the post-partum period wherein elevated c-Met protein levels
persist in the normal mammary gland and are not down-regulated
after resolution of involution, therefore creating fertile grounds for
the development of HGF/c-Met-driven BBC. The role of c-Met
signaling in BBC is currently under investigation. Future studies
will be aimed at examining multiple time points from before tumor
formation throughout tumor growth.
Insulin resistance has been hypothesized to increase breast
cancer risk [52,53]. In our study, obesity did not induce significant
differences in hyperglycemia, hyperinsulinemia or insulin resis-
tance indicating that these metabolic parameters do not play a role
in the development of tumors in parous C3(1)-TAg GEMM.
Likewise, there were no significant differences between nulliparous
and parous mice, indicating that glucose and insulin plasma
concentrations did not affect parity-induced reductions in latency.
In this study, a significant elevation in systemic IL-6 concentra-
tions in obese mice suggested a potential role for inflammation in
tumor onset in parous C3(1)-TAg mice. Obesity did not induce
significant differences in TNF-a and MCP-1 concentrations in
parous mice. However, compared to the obese nulliparous mice
[35], TNF-a concentrations were 5-fold greater in obese parous
mice. Elevations in TNF-a and IL-6 in these mice suggest that
inflammation is one pathway that may mediate effects of parity on
reduced latency. Future studies examining local and systemic
inflammation-mediated effects on BBC are needed to clarify the
contribution to tumor onset. Finally, estrogen and progesterone
concentrations likely do not contribute to the observed tumor
latency differences induced by parity compared to nulliparous
mice or obesity in parous mice.
In summary, our studies demonstrate that, similar to epidemi-
ologic reports [7], parity dramatically reduced BBC latency
compared to nulliparous mice and, importantly, obesity further
accelerated subsequent tumor appearance. Obesity-elevated c-Met
protein expression in normal mammary gland implicates a role for
this growth factor pathway in the etiology of BBC. Further studies
will test inhibition of c-Met signaling in the onset of post-partum
obesity-driven BBC. Because BBC has unique risk factors that in
many cases are traditionally thought of as breast cancer preventive
factors [35], future studies should investigate the role of weight
gain or loss in the post-partum period as modifiable BBC risk
factors.
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